Sana Biotechnology Archives · BioBuzz

MaxCyte Cell-Engineering Platform Boosts Development Programs of 14 Different Companies

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/08/maxcyte-expert-featured-img-300x300.png?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/08/maxcyte-expert-featured-img-75x75.png?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/08/maxcyte-expert-featured-img-150x150.png?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/08/maxcyte-expert-featured-img.png?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/08/maxcyte-expert-featured-img-300x300.png?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : August 16, 2021August 16, 2021 Published by : Alex Keown

The next major wave of treatment options for multiple diseases is cell therapies, and Gaithersburg-based MaxCyte is one of the companies driving this revolution.

Gaithersburg’s MaxCyte Signs Clinical and Commercial License with Seattle’s Sana Biotechnology

<img width="300" height="210" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/MAXCYTE_Logo-scaled-e1664389524459-300x210.jpg?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/MAXCYTE_Logo-scaled-e1664389524459.jpg?size=60x42&lossy=1&strip=1&webp=1 60w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/MAXCYTE_Logo-scaled-e1664389524459.jpg?size=120x84&lossy=1&strip=1&webp=1 120w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/MAXCYTE_Logo-scaled-e1664389524459.jpg?size=180x126&lossy=1&strip=1&webp=1 180w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/MAXCYTE_Logo-scaled-e1664389524459.jpg?size=240x168&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/MAXCYTE_Logo-scaled-e1664389524459-300x210.jpg?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : August 9, 2021August 9, 2021 Published by : BioBuzz Media

MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.